Invasive Fungal Diseases Caused By Rare Pathogens In Patients After Hematopoietic Stem Cell Transplantation (Hsct) & Chemotherapy

of the non-first-line without bone marrow transplantation) (P < 0.001) ), 0.681 times (P < 0.001), 0.724 times (P ¼ 0.035).Conclusions: In conclusion, our study showed that the first-line effect of bortezomibbased therapy on clinical outcomes for Taiwanese patients with multiple myeloma was better than the non-first line.To provide the most representative data on Bortezomib treatment results of MM patients achievable in Taiwan, we could prospectively collect nationwide data including detailed information.This could not only provide stagestratified survival and disease-specific survival rates but also help to identify better clinical effects.